> ## Content Index
> Fetch the complete content index at: https://www.healthdatacon.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Expands Clinical Trial Disclosures
- URL: https://www.healthdatacon.io/articles/fda-expands-clinical-trial-disclosures/
- Published: 2012-01-12T17:13:31.000Z
- Updated: 2012-01-12T17:13:31.000Z
- Description: Research subjects in clinical trials must be informed of certain financial arrangements or prior misconduct of clinical investigators, the FDA has announced.
- Author: Joseph Goedert
- Tags: Informatics

Research subjects in clinical trials must be informed of certain financial arrangements or prior misconduct of clinical investigators, the FDA has announced.  
  
The disclosures are part of a series of mostly routine changes to the Bioresearch Monitoring Information System that tracks clinical investigators’ compliance with FDA regulations. The agency published a notice of changes Jan. 9 in the [Federal Register](http://www.gpo.gov/fdsys/pkg/FR-2012-01-09/html/2012-114.htm?ref=healthdatacon.io). The changes in disclosures to research subjects include:  
  
\* “Providing for disclosure to a research subject of information from a research misconduct proceeding that may have implications for that subject’s rights, safety or welfare, or participation in a research study,” and  
  
\* “Providing for disclosure to the public of information related to a clinical investigator’s financial arrangement with or interests in a study sponsor, to the extent disclosure is not an unwarranted invasion of personal privacy or is not otherwise protected from disclosure under FDA’s regulations or applicable statutes.”